chevron_leftBack
As of 5 June 2026, Spago Nanomedical AB (publ) has a market cap of $8.02M USD, ranking #42411 globally and #671 in Sweden.
It ranks #3751 in the Healthcare sector, and #740 in the Biotechnology industry.
Key Stats
Market Cap
$8.02MUSD
75.42M SEK
Enterprise Value
$4.88MUSD
45.75M SEK
Revenue (TTM)
$512.62KUSD
4.82M SEK
EBITDA (TTM)
-$2.86MUSD
-26.78M SEK
Net Income (TTM)
-$2.82MUSD
-26.55M SEK
PS Ratio
15.6
PB Ratio
2.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Mats Hansen
open_in_new
Employees
7
Founded
1999
Website
spagonanomedical.se
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -0.4% | 17% | -8.5% | -51% | -43% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
SPAGO
Spago Nanomedical AB
ISIN: SE0004899474
Shares Out.:
Shares Outstanding:
808.589M1
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.1125 SEK |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Spago Nanomedical AB (publ)
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. The company was incorporated in 1999 and is based in Lund, Sweden.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
STO: VIMIAN
|
$1.58B
20K%
14.9B SEK
|
43.7
|
|
STO: BINV
|
$150.75M
2K%
1.42B SEK
|
-
|
|
STO: BICO
|
$141.2M
2K%
1.33B SEK
|
-
|
|
STO: CINPHA
|
$60.16M
650%
565.9M SEK
|
-
|
|
STO: IVACC
|
$41.67M
420%
391.94M SEK
|
-
|
|
NGM: BIOWKS
|
$32.98M
311%
310.2M SEK
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
2M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
2M%
|
19.0
|
|
EBR: ARGX
|
$48.01B
599K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.48B
555K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$43.01B
536K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.55B
531K%
33.71B CHF
|
37.2
|
chevron_leftBack